文献速递泌尿生殖与妇科肿瘤放疗

NRG肿瘤学RTOG 0938研究:评估两种超大分割方案治疗前列腺癌的五年患者报告结局

Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-12-31

RTOG 0938是一项非盲随机2期研究,纳入国家综合癌症网络低危前列腺癌患者,分别接受5次(7.25 Gy,2周加1天,每周两次)或12次(4.3 Gy,2.5周,每周五次)放疗,采用EPIC-50量表评估5年患者报告毒性。结果显示两种方案肠道和泌尿域长期变化及毒性均耐受良好,但作者认为需与当前标准放疗方案比较。

要点

  • 5次组肠道评分>5分变化5年频率为38.4%(P=0.27),12次组为23.4%(P=0.98)。
  • 5次组泌尿评分>2分变化5年频率为46.6%(P=0.15),12次组为36.4%(P=0.70)。
  • 5次组性功能评分下降≥11分者占49.3%(P=0.007),12次组占54%(P<0.001)。

核心结论

  • 基于肠道和泌尿域的长期变化及毒性,5次和12次超大分割方案均耐受良好。
  • 作者认为这些超大分割方案需与当前标准放疗方案进行比较。

研究设计与样本

  • NRG肿瘤学RTOG 0938是一项非盲随机2期研究,纳入国家综合癌症网络低危前列腺癌患者,每个治疗组与历史对照比较。
  • 患者随机接受5次(7.25 Gy,2周加1天,每周两次)或12次(4.3 Gy,2.5周,每周五次)放疗。
  • 5次组入组127例(121例符合方案),12次组入组128例(125例符合方案);分析时所有患者中位随访5.38年。

主要发现

  • 5次组肠道评分>5分变化5年频率为38.4%(P=0.27),12次组为23.4%(P=0.98)。
  • 5次组泌尿评分>2分变化5年频率为46.6%(P=0.15),12次组为36.4%(P=0.70)。
  • 5次组49.3%(P=0.007)患者5年EPIC-50性功能评分下降≥11分;12次组54%(P<0.001)患者下降≥11分。
  • 5年无病生存率5次组为89.6%(95%CI:84.0-95.2),12次组为92.3%(95%CI:87.4-97.1)。
  • 未发生4级或5级晚期治疗相关泌尿或肠道毒性。

关键数值与推荐

  • 采用卡方检验评估肠道评分>5分、泌尿评分>2分、性功能评分>11分较基线下降的患者比例。
  • 5次方案为7.25 Gy×5次,2周加1天,每周两次;12次方案为4.3 Gy×12次,2.5周,每周五次。

局限性

  • 作者结论指出这些超大分割方案需与当前标准放疗方案进行比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is considerable interest in very short (ultrahypofractionated) radiation therapy regimens to treat prostate cancer based on potential radiobiological advantages, patient convenience, and resource allocation benefits. Our objective is to demonstrate that detectable changes in health-related quality of life measured by the bowel and urinary domains of the Expanded Prostate Cancer Index Composite (EPIC-50) were not substantially worse than baseline scores. METHODS AND MATERIALS: NRG Oncology's RTOG 0938 is a nonblinded randomized phase 2 study of National Comprehensive Cancer Network low-risk prostate cancer in which each arm is compared with a historical control. Patients were randomized to 5 fractions (7.25 Gy in 2 week and a day [twice a week]) or 12 fractions (4.3Gy in 2.5 weeks [5 times a week]). Secondary objectives assessed patient-reported toxicity at 5 years using the EPIC. Chi-square tests were used to assess the proportion of patients with a deterioration from baseline of >5 points for bowel, >2 points for urinary, and >11 points for sexual score. RESULTS: The study enrolled 127 patients to 5 fractions (121 eligible) and 128 patients to 12 fractions (125 eligible). The median follow-up for all patients at the time of analysis was 5.38 years. The 5-year frequency for >5 point change in bowel score were 38.4% (P = .27) and 23.4% (P = 0.98) for 5 and 12 fractions, respectively. The 5-year frequencies for >2 point change in urinary score were 46.6% (P = .15) and 36.4% (P = .70) for 5 and 12 fractions, respectively. For 5 fractions, 49.3% (P = .007) of patients had a drop in 5-year EPIC-50 sexual score of ≥11 points; for 12 fractions, 54% (P < .001) of patients had a drop in 5-year EPIC-50 sexual score of ≥11 points. Disease-free survival at 5 years is 89.6% (95% CI: 84.0-95.2) in the 5-fraction arm and 92.3% (95% CI: 87.4-97.1) in the 12-fraction arm. There was no late grade 4 or 5 treatment-related urinary or bowel toxicity. CONCLUSIONS: This study confirms that, based on long-term changes in bowel and urinary domains and toxicity, the 5- and 12-fraction regimens are well tolerated. These ultrahypofractionated approaches need to be compared with current standard radiation therapy regimens.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Lukka HR, Deshmukh S, Bruner DW, et al. Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 36592721. doi:10.1016/j.ijrobp.2022.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。